nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—SIGMAR1—amyotrophic lateral sclerosis	0.877	1	CbGaD
Raloxifene—Uterine haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00756	0.0881	CcSEcCtD
Raloxifene—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00412	0.0479	CcSEcCtD
Raloxifene—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00366	0.0427	CcSEcCtD
Raloxifene—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0353	CcSEcCtD
Raloxifene—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0336	CcSEcCtD
Raloxifene—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00264	0.0308	CcSEcCtD
Raloxifene—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00243	0.0283	CcSEcCtD
Raloxifene—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.0022	0.0257	CcSEcCtD
Raloxifene—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00197	0.023	CcSEcCtD
Raloxifene—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00189	0.022	CcSEcCtD
Raloxifene—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00173	0.0202	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00173	0.0201	CcSEcCtD
Raloxifene—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0193	CcSEcCtD
Raloxifene—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0186	CcSEcCtD
Raloxifene—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0176	CcSEcCtD
Raloxifene—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0173	CcSEcCtD
Raloxifene—Depression—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0172	CcSEcCtD
Raloxifene—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0167	CcSEcCtD
Raloxifene—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00142	0.0165	CcSEcCtD
Raloxifene—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0161	CcSEcCtD
Raloxifene—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00133	0.0155	CcSEcCtD
Raloxifene—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0154	CcSEcCtD
Raloxifene—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0153	CcSEcCtD
Raloxifene—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0153	CcSEcCtD
Raloxifene—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0152	CcSEcCtD
Raloxifene—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0152	CcSEcCtD
Raloxifene—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0151	CcSEcCtD
Raloxifene—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0143	CcSEcCtD
Raloxifene—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0012	0.014	CcSEcCtD
Raloxifene—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0133	CcSEcCtD
Raloxifene—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0129	CcSEcCtD
Raloxifene—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0121	CcSEcCtD
Raloxifene—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00104	0.0121	CcSEcCtD
Raloxifene—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0118	CcSEcCtD
Raloxifene—Cough—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0117	CcSEcCtD
Raloxifene—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000983	0.0115	CcSEcCtD
Raloxifene—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000983	0.0115	CcSEcCtD
Raloxifene—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000983	0.0115	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000976	0.0114	CcSEcCtD
Raloxifene—Infection—Riluzole—amyotrophic lateral sclerosis	0.000936	0.0109	CcSEcCtD
Raloxifene—Shock—Riluzole—amyotrophic lateral sclerosis	0.000927	0.0108	CcSEcCtD
Raloxifene—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000924	0.0108	CcSEcCtD
Raloxifene—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000923	0.0107	CcSEcCtD
Raloxifene—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000915	0.0107	CcSEcCtD
Raloxifene—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000911	0.0106	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000859	0.01	CcSEcCtD
Raloxifene—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000852	0.00993	CcSEcCtD
Raloxifene—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00083	0.00966	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00948	CcSEcCtD
Raloxifene—Pain—Riluzole—amyotrophic lateral sclerosis	0.000806	0.00939	CcSEcCtD
Raloxifene—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000771	0.00898	CcSEcCtD
Raloxifene—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00868	CcSEcCtD
Raloxifene—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00868	CcSEcCtD
Raloxifene—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000645	0.00751	CcSEcCtD
Raloxifene—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00726	CcSEcCtD
Raloxifene—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000599	0.00698	CcSEcCtD
Raloxifene—Rash—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00692	CcSEcCtD
Raloxifene—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00691	CcSEcCtD
Raloxifene—Headache—Riluzole—amyotrophic lateral sclerosis	0.00059	0.00688	CcSEcCtD
Raloxifene—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00056	0.00652	CcSEcCtD
Raloxifene—ESR2—hindbrain—amyotrophic lateral sclerosis	0.0005	0.104	CbGeAlD
Raloxifene—ESR1—hindbrain—amyotrophic lateral sclerosis	0.000343	0.0711	CbGeAlD
Raloxifene—ESR2—brainstem—amyotrophic lateral sclerosis	0.000287	0.0595	CbGeAlD
Raloxifene—ESR1—embryo—amyotrophic lateral sclerosis	0.000214	0.0445	CbGeAlD
Raloxifene—HTR6—nervous system—amyotrophic lateral sclerosis	0.000214	0.0444	CbGeAlD
Raloxifene—HTR6—central nervous system—amyotrophic lateral sclerosis	0.000206	0.0428	CbGeAlD
Raloxifene—ESR1—brainstem—amyotrophic lateral sclerosis	0.000196	0.0408	CbGeAlD
Raloxifene—HTR6—brain—amyotrophic lateral sclerosis	0.000164	0.034	CbGeAlD
Raloxifene—EBP—Metabolism—DAO—amyotrophic lateral sclerosis	0.000159	0.00496	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000157	0.00489	CbGpPWpGaD
Raloxifene—SIGMAR1—medulla oblongata—amyotrophic lateral sclerosis	0.000155	0.0322	CbGeAlD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000153	0.00478	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—GFAP—amyotrophic lateral sclerosis	0.000153	0.00477	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000152	0.00474	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—ZNF746—amyotrophic lateral sclerosis	0.000151	0.0047	CbGpPWpGaD
Raloxifene—ESR2—nervous system—amyotrophic lateral sclerosis	0.00015	0.0312	CbGeAlD
Raloxifene—AOX1—Disease—TPK1—amyotrophic lateral sclerosis	0.000145	0.00453	CbGpPWpGaD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—IGF1—amyotrophic lateral sclerosis	0.000145	0.00451	CbGpPWpGaD
Raloxifene—ESR2—central nervous system—amyotrophic lateral sclerosis	0.000145	0.03	CbGeAlD
Raloxifene—ESR2—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000144	0.00448	CbGpPWpGaD
Raloxifene—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—amyotrophic lateral sclerosis	0.000142	0.00443	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000141	0.00441	CbGpPWpGaD
Raloxifene—ESR2—cerebellum—amyotrophic lateral sclerosis	0.000141	0.0294	CbGeAlD
Raloxifene—SIGMAR1—spinal cord—amyotrophic lateral sclerosis	0.000138	0.0287	CbGeAlD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—amyotrophic lateral sclerosis	0.000136	0.00425	CbGpPWpGaD
Raloxifene—AOX1—cerebellum—amyotrophic lateral sclerosis	0.000136	0.0283	CbGeAlD
Raloxifene—ESR1—Validated nuclear estrogen receptor alpha network—C3—amyotrophic lateral sclerosis	0.000132	0.00411	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000129	0.00403	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000129	0.00403	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000123	0.00385	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000122	0.0038	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000122	0.0038	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00012	0.00376	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00012	0.00375	CbGpPWpGaD
Raloxifene—CYP19A1—nervous system—amyotrophic lateral sclerosis	0.000118	0.0246	CbGeAlD
Raloxifene—CYP2B6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000118	0.00368	CbGpPWpGaD
Raloxifene—AOX1—Disease—VTA1—amyotrophic lateral sclerosis	0.000116	0.00363	CbGpPWpGaD
Raloxifene—HTR2B—nervous system—amyotrophic lateral sclerosis	0.000116	0.0241	CbGeAlD
Raloxifene—ESR2—brain—amyotrophic lateral sclerosis	0.000115	0.0238	CbGeAlD
Raloxifene—CYP19A1—central nervous system—amyotrophic lateral sclerosis	0.000114	0.0237	CbGeAlD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000113	0.00353	CbGpPWpGaD
Raloxifene—HTR2B—central nervous system—amyotrophic lateral sclerosis	0.000112	0.0232	CbGeAlD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000111	0.00348	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000111	0.00347	CbGpPWpGaD
Raloxifene—EBP—Metabolism—GSR—amyotrophic lateral sclerosis	0.000111	0.00347	CbGpPWpGaD
Raloxifene—AOX1—brain—amyotrophic lateral sclerosis	0.000111	0.0229	CbGeAlD
Raloxifene—CYP2C8—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.00011	0.00344	CbGpPWpGaD
Raloxifene—SIGMAR1—cerebellum—amyotrophic lateral sclerosis	0.00011	0.0227	CbGeAlD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000109	0.00342	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000109	0.00341	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000109	0.00341	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000106	0.00331	CbGpPWpGaD
Raloxifene—ESR1—Plasma membrane estrogen receptor signaling—MMP9—amyotrophic lateral sclerosis	0.000105	0.00328	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000104	0.00325	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000104	0.00323	CbGpPWpGaD
Raloxifene—ESR1—nervous system—amyotrophic lateral sclerosis	0.000103	0.0214	CbGeAlD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000102	0.00317	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000101	0.00316	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.0001	0.00312	CbGpPWpGaD
Raloxifene—CYP2C8—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	9.98e-05	0.00311	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	9.96e-05	0.00311	CbGpPWpGaD
Raloxifene—ESR1—central nervous system—amyotrophic lateral sclerosis	9.91e-05	0.0206	CbGeAlD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	9.79e-05	0.00305	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—FIG4—amyotrophic lateral sclerosis	9.73e-05	0.00304	CbGpPWpGaD
Raloxifene—ESR1—cerebellum—amyotrophic lateral sclerosis	9.68e-05	0.0201	CbGeAlD
Raloxifene—ESR1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	9.56e-05	0.00298	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	9.32e-05	0.00291	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—CASP9—amyotrophic lateral sclerosis	9.27e-05	0.00289	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—FUS—amyotrophic lateral sclerosis	9.26e-05	0.00289	CbGpPWpGaD
Raloxifene—EBP—Metabolism—CHAT—amyotrophic lateral sclerosis	9.12e-05	0.00285	CbGpPWpGaD
Raloxifene—CYP19A1—brain—amyotrophic lateral sclerosis	9.05e-05	0.0188	CbGeAlD
Raloxifene—ESR2—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	8.97e-05	0.0028	CbGpPWpGaD
Raloxifene—SIGMAR1—brain—amyotrophic lateral sclerosis	8.9e-05	0.0185	CbGeAlD
Raloxifene—HTR2B—brain—amyotrophic lateral sclerosis	8.88e-05	0.0184	CbGeAlD
Raloxifene—AOX1—Disease—CHMP2B—amyotrophic lateral sclerosis	8.81e-05	0.00275	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—DAO—amyotrophic lateral sclerosis	8.8e-05	0.00275	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	8.62e-05	0.00269	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	8.49e-05	0.00265	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	8.38e-05	0.00261	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	8.32e-05	0.0026	CbGpPWpGaD
Raloxifene—CYP19A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.22e-05	0.00256	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—SMN1—amyotrophic lateral sclerosis	8.13e-05	0.00254	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	8.11e-05	0.00253	CbGpPWpGaD
Raloxifene—CYP19A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.1e-05	0.00253	CbGpPWpGaD
Raloxifene—AOX1—Disease—PLB1—amyotrophic lateral sclerosis	7.97e-05	0.00248	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—ERBB4—amyotrophic lateral sclerosis	7.94e-05	0.00248	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	7.91e-05	0.00247	CbGpPWpGaD
Raloxifene—ESR1—brain—amyotrophic lateral sclerosis	7.86e-05	0.0163	CbGeAlD
Raloxifene—HTR2B—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	7.75e-05	0.00242	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.75e-05	0.00242	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.72e-05	0.00241	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	7.69e-05	0.0024	CbGpPWpGaD
Raloxifene—CYP2B6—nervous system—amyotrophic lateral sclerosis	7.6e-05	0.0158	CbGeAlD
Raloxifene—ESR2—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	7.58e-05	0.00237	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—RARA—amyotrophic lateral sclerosis	7.55e-05	0.00236	CbGpPWpGaD
Raloxifene—CYP2B6—central nervous system—amyotrophic lateral sclerosis	7.32e-05	0.0152	CbGeAlD
Raloxifene—ESR1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	7.25e-05	0.00226	CbGpPWpGaD
Raloxifene—AOX1—Disease—VCP—amyotrophic lateral sclerosis	7.1e-05	0.00221	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.03e-05	0.00219	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.95e-05	0.00217	CbGpPWpGaD
Raloxifene—ESR1—LKB1 signaling events—TP53—amyotrophic lateral sclerosis	6.88e-05	0.00214	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	6.86e-05	0.00214	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PLB1—amyotrophic lateral sclerosis	6.67e-05	0.00208	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.54e-05	0.00204	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.51e-05	0.00203	CbGpPWpGaD
Raloxifene—CYP2C8—brain—amyotrophic lateral sclerosis	6.48e-05	0.0135	CbGeAlD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.45e-05	0.00201	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	6.44e-05	0.00201	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.3e-05	0.00196	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.3e-05	0.00196	CbGpPWpGaD
Raloxifene—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.22e-05	0.00194	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.22e-05	0.00194	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GSR—amyotrophic lateral sclerosis	6.16e-05	0.00192	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.14e-05	0.00192	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.87e-05	0.00183	CbGpPWpGaD
Raloxifene—CYP2B6—brain—amyotrophic lateral sclerosis	5.81e-05	0.0121	CbGeAlD
Raloxifene—CYP19A1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.76e-05	0.0018	CbGpPWpGaD
Raloxifene—CYP3A4—nervous system—amyotrophic lateral sclerosis	5.74e-05	0.0119	CbGeAlD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.7e-05	0.00178	CbGpPWpGaD
Raloxifene—CYP3A4—central nervous system—amyotrophic lateral sclerosis	5.53e-05	0.0115	CbGeAlD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.47e-05	0.00171	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	5.36e-05	0.00167	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.35e-05	0.00167	CbGpPWpGaD
Raloxifene—CYP2B6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.28e-05	0.00165	CbGpPWpGaD
Raloxifene—CYP2B6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.2e-05	0.00162	CbGpPWpGaD
Raloxifene—AOX1—Disease—CST3—amyotrophic lateral sclerosis	5.1e-05	0.00159	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—CHAT—amyotrophic lateral sclerosis	5.06e-05	0.00158	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.03e-05	0.00157	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	5.02e-05	0.00157	CbGpPWpGaD
Raloxifene—EBP—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.9e-05	0.00153	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.87e-05	0.00152	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.8e-05	0.0015	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—FUS—amyotrophic lateral sclerosis	4.67e-05	0.00146	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	4.66e-05	0.00145	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—DAO—amyotrophic lateral sclerosis	4.55e-05	0.00142	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	4.52e-05	0.00141	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.51e-05	0.00141	CbGpPWpGaD
Raloxifene—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.47e-05	0.00139	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.44e-05	0.00139	CbGpPWpGaD
Raloxifene—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.41e-05	0.00137	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	4.39e-05	0.00137	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.38e-05	0.00137	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.36e-05	0.00136	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.23e-05	0.00132	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.21e-05	0.00131	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.14e-05	0.00129	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.04e-05	0.00126	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.04e-05	0.00126	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.98e-05	0.00124	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.93e-05	0.00122	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—RARA—amyotrophic lateral sclerosis	3.81e-05	0.00119	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.72e-05	0.00116	CbGpPWpGaD
Raloxifene—EBP—Metabolism—APOE—amyotrophic lateral sclerosis	3.71e-05	0.00116	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.71e-05	0.00116	CbGpPWpGaD
Raloxifene—AOX1—Disease—CASP9—amyotrophic lateral sclerosis	3.7e-05	0.00116	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.7e-05	0.00115	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.5e-05	0.00109	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.45e-05	0.00108	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.44e-05	0.00107	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	3.42e-05	0.00107	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	3.42e-05	0.00107	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.4e-05	0.00106	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.38e-05	0.00106	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.33e-05	0.00104	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.25e-05	0.00101	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.23e-05	0.00101	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.19e-05	0.000996	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.19e-05	0.000996	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSR—amyotrophic lateral sclerosis	3.18e-05	0.000993	CbGpPWpGaD
Raloxifene—AOX1—Disease—ERBB4—amyotrophic lateral sclerosis	3.17e-05	0.000989	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	3.13e-05	0.000977	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.1e-05	0.000967	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.03e-05	0.000944	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.93e-05	0.000914	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—DAO—amyotrophic lateral sclerosis	2.92e-05	0.000912	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.91e-05	0.000909	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.91e-05	0.000908	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.9e-05	0.000904	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.81e-05	0.000877	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.76e-05	0.000862	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.76e-05	0.000861	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	2.74e-05	0.000854	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.72e-05	0.000848	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.68e-05	0.000835	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.61e-05	0.000816	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.6e-05	0.000812	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.58e-05	0.000806	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.57e-05	0.000803	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.54e-05	0.000792	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.52e-05	0.000785	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.5e-05	0.000779	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	2.47e-05	0.000772	CbGpPWpGaD
Raloxifene—AOX1—Disease—APOE—amyotrophic lateral sclerosis	2.45e-05	0.000765	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.43e-05	0.000757	CbGpPWpGaD
Raloxifene—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.4e-05	0.000748	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.39e-05	0.000744	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.38e-05	0.000741	CbGpPWpGaD
Raloxifene—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.36e-05	0.000738	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.35e-05	0.000733	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.3e-05	0.000718	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.23e-05	0.000695	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.22e-05	0.000691	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.15e-05	0.000671	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.09e-05	0.000653	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.09e-05	0.000651	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—APOE—amyotrophic lateral sclerosis	2.05e-05	0.000641	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSR—amyotrophic lateral sclerosis	2.04e-05	0.000638	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.98e-05	0.000617	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.96e-05	0.000613	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.96e-05	0.00061	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.91e-05	0.000596	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.9e-05	0.000593	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	1.88e-05	0.000585	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.84e-05	0.000573	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.84e-05	0.000573	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.77e-05	0.000552	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.74e-05	0.000542	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	1.73e-05	0.00054	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—amyotrophic lateral sclerosis	1.68e-05	0.000524	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.68e-05	0.000524	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.68e-05	0.000524	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.66e-05	0.000517	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.63e-05	0.00051	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.61e-05	0.000504	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.58e-05	0.000493	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.58e-05	0.000492	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.56e-05	0.000487	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.51e-05	0.000472	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.47e-05	0.000458	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.44e-05	0.00045	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.42e-05	0.000443	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.41e-05	0.000439	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.41e-05	0.000438	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.35e-05	0.000422	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.34e-05	0.000419	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.33e-05	0.000414	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.3e-05	0.000405	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.29e-05	0.000403	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.27e-05	0.000397	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.26e-05	0.000393	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.23e-05	0.000385	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.2e-05	0.000375	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.16e-05	0.000362	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.12e-05	0.00035	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.06e-05	0.000331	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.05e-05	0.000326	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.03e-05	0.000321	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.03e-05	0.00032	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.01e-05	0.000314	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.67e-06	0.000302	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.55e-06	0.000298	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	9.29e-06	0.00029	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.02e-06	0.000281	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.89e-06	0.000277	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.64e-06	0.00027	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.54e-06	0.000266	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.29e-06	0.000259	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.95e-06	0.000248	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.89e-06	0.000246	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.64e-06	0.000238	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	7.63e-06	0.000238	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.28e-06	0.000227	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.02e-06	0.000219	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—APOE—amyotrophic lateral sclerosis	6.82e-06	0.000213	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.65e-06	0.000208	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.57e-06	0.000205	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.29e-06	0.000196	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.07e-06	0.000189	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	5.78e-06	0.00018	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.74e-06	0.000179	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.64e-06	0.000176	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.15e-06	0.000161	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.06e-06	0.000158	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.78e-06	0.000149	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.67e-06	0.000146	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.29e-06	0.000134	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.27e-06	0.000133	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.1e-06	0.000128	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.96e-06	0.000123	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.89e-06	0.000121	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.77e-06	0.000118	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.24e-06	0.000101	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.1e-06	9.67e-05	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.12e-06	6.63e-05	CbGpPWpGaD
